Literature DB >> 25024807

Primary perivascular epithelioid cell tumour (PEComa) of the prostate.

Alper Eken1, Yesim Saglican2.   

Abstract

Perivascular epithelioid cell tumours (PEComas) are a family of rare mesenchymal tumours arising in various anatomic locations. PEComas are defined by the presence of perivascular epithelioid cells that coexpress muscle and melanotic markers, especially HMB-45. They have unpredictable biological behaviour and are mostly benign, but some tumours can become unresectable or metastatic. Surgical resection, when possible, is the best treatment option. Radiation therapy, cytotoxic chemotherapy or immunotherapy have been reported as treatment options, either alone or in combination therapy. Prostatic PEComa is extremely rare, with only 1 malignant case reported. We report the first case of prostatic PEComa, which was benign and treated with transurethral resection.

Entities:  

Year:  2014        PMID: 25024807      PMCID: PMC4081268          DOI: 10.5489/cuaj.1752

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  8 in total

1.  PEC and sugar.

Authors:  F Bonetti; M Pea; G Martignoni; G Zamboni
Journal:  Am J Surg Pathol       Date:  1992-03       Impact factor: 6.394

Review 2.  Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.

Authors:  Andrew L Folpe; Thomas Mentzel; Hans-Anton Lehr; Cyril Fisher; Bonnie L Balzer; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2005-12       Impact factor: 6.394

3.  Clear cell myomelanocytic tumor of the falciform ligament/ligamentum teres: a novel member of the perivascular epithelioid clear cell family of tumors with a predilection for children and young adults.

Authors:  A L Folpe; Z D Goodman; K G Ishak; A F Paulino; E M Taboada; S A Meehan; S W Weiss
Journal:  Am J Surg Pathol       Date:  2000-09       Impact factor: 6.394

4.  Malignant perivascular epithelioid cell tumor of the mesentery: a case report and literature review.

Authors:  Chien-Liang Lai; Kuo-Feng Hsu; Jyh-Cherng Yu; Cheng-Jueng Chen; Chung-Bao Hsieh; De-Chuan Chan; Heng-Sheng Li; Hung-Ming Hsu
Journal:  Onkologie       Date:  2012-02-20

5.  Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate.

Authors:  Heather Rigby; Weiming Yu; Matthias H Schmidt; Conrad V Fernandez
Journal:  Pediatr Blood Cancer       Date:  2005-08       Impact factor: 3.167

Review 6.  Malignant perivascular epithelioid cell tumor involving the prostate.

Authors:  Chin-Chen Pan; An-Hang Yang; Hung Chiang
Journal:  Arch Pathol Lab Med       Date:  2003-02       Impact factor: 5.534

Review 7.  Perivascular epithelioid cell neoplasm of the urinary bladder in an adolescent: a case report and review of the literature.

Authors:  Lijuan Yin; Hong Bu; Min Chen; Jianqun Yu; Hua Zhuang; Jie Chen; Hongying Zhang
Journal:  Diagn Pathol       Date:  2012-12-31       Impact factor: 2.644

8.  Primary PEComa of the bladder treated with primary excision and adjuvant interferon-alpha immunotherapy: a case report.

Authors:  Jeremy R Parfitt; Anthony J Bella; Bret M Wehrli; Jonathan I Izawa
Journal:  BMC Urol       Date:  2006-08-22       Impact factor: 2.264

  8 in total
  3 in total

1.  Expression of CD44 and CD29 by PEComa cells suggests their possible origin of mesenchymal stem cells.

Authors:  Ruixue Liu; Wei Jia; Hong Zou; Xinhua Wang; Yan Ren; Jin Zhao; Lianghai Wang; Man Li; Yan Qi; Yaoyuan Shen; Weihua Liang; Jinfang Jiang; Zhenzhu Sun; Lijuan Pang; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Malignant perivascular epithelioid cell tumor of the kidney with rare pulmonary and ileum metastases.

Authors:  Huijuan Shi; Qinghua Cao; Hui Li; Tiantian Zhen; Yingrong Lai; Anjia Han
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Pigmented perivascular epithelioid cell tumor (PEComa) arising from kidney: A case report.

Authors:  Hexi Du; Jun Zhou; Lingfan Xu; Cheng Yang; Li Zhang; Chaozhao Liang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.